𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

Page d'Accueil
België
Brussels
𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

An 𝓲𝓷𝓲𝓽𝓲𝓪𝓽𝓲𝓿𝓮 that encourages 𝕋𝔼𝔸𝕄𝕎𝕆ℝ𝕂 towards «science, education and technology».

01/09/2026

"𝗝𝐨𝐮𝐫𝐧𝐚𝐥 𝗥𝐞𝐯𝐢𝐞𝐰 (𝐉𝐑)
----------------------------------------------
Performed on: Monday, July 20, 2026
𝟐𝟎𝟐𝟔 𝐍𝐄𝐉𝐌𝐜 - 𝐄𝐧𝐝𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐟𝐨𝐫 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰_𝐏𝐨𝐬𝐭-𝐓𝐡𝐫𝐨𝐦𝐛𝐨𝐭𝐢𝐜 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞 (𝐍𝐄𝐉𝐌).𝐩𝐝𝐟

1. 𝙄𝙌𝘾 𝙨𝙘𝙤𝙥𝙚 ▶︎ Y, J, C ➖ T ➕ N ➕ t ➖ P I C O:
2. 2026, NEJM, ❓ ➖ RCT ➕ 225 pxs ➕ ❓(ƒ-up 6m) ➖ P I C O:
🅿: adults w_mod-to-sev PTS + image (iliac-vein obstruction)
🅸: endovascular therapy
🅲: no endovascular therapy
🅾: pOC = change in the ‘30-point VCSS’
3. EVIDENCE:
a. PTS af_acute lower-extremity DVT:
i. pain
ii. pruritus
iii. edema
iv. ulceration
b. Common in PROXIMAL DVT → iliac-vein obstruction
4. METHODS.
🅸
- iliac-vein stent
- antiCOA ≥6m
- aspirin
- knowledge
Both 🅸 + 🅲 received SOC
SOC = knee-high compression stockings + antiCOA according to r f_recurrent DVT
5. RESULTS.
a. Baseline → 🅾 12 pts
b. 6m → 🅾 (p common → 12%
ii. 🅲 < common → 4%
e. More-potent antithrombotic TTO
i. 🅸 71%
ii. 🅲 21%
6. RATIONALE
a. Less-experienced operators may NOT APPLY to this study.
b. Notice:
7. SOURCE ▶︎ Vedantham S, et al. Endovascular therapy for post-thrombotic syndrome — A randomized trial. N Engl J Med 2026 Apr 13; [e-pub]. DOI: 10.1056/NEJMoa2519001.
𝗩𝗲𝗿 𝗺á𝘀 𝗲𝗻: https://www.inaaqc.org/journal_reviews_2026"

31/08/2026

👋 ¡¡𝐇𝐨𝐥𝐚! 𝐓𝐞 𝐜𝐨𝐦𝐩𝐚𝐫𝐭𝐢𝐦𝐨𝐬 𝐮𝐧𝐚 𝐢𝐧𝐯𝐢𝐭𝐚𝐜𝐢ó𝐧 𝐢𝐦𝐩𝐞𝐫𝐝𝐢𝐛𝐥𝐞🧬🔬

*Conferencia Virtual: “Nuevas Tecnologías para la Detección de Virus”*

La biotecnología sigue avanzando a pasos agigantados, y en esta conferencia conocerás de primera mano las innovaciones más recientes aplicadas a la detección temprana de virus.

🎙 Expositora: Jimena Zubieta Rojas — Bioquímica, Magíster en Biotecnología Bioquímica e investigadora en virología molecular.

🏛 Organizan: UPB IEEE Student Branch & IEEE EMBS

📅 Fecha: 01 de Septiembre, 2026
⏰ Hora: 19:30pm
💻 Modalidad: Online, abierta a todo público interesado

No necesitas experiencia previa en el tema, ¡solo muchas ganas de aprender! 🌱

Inscríbete directamente aquí:
👉 https://forms.gle/MV9qfC1S23aoaKN27

29/08/2026

E-learning | 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ
---------------------------------
𝙵𝙾𝚁 𝙷𝙴𝙰𝙻𝚃𝙷𝙲𝙰𝚁𝙴 𝙿𝚁𝙾𝚅𝙸𝙳𝙴𝚁𝚂 / 𝙿𝙰𝚁𝙰 𝙿𝚁𝙾𝚅𝙴𝙴𝙳𝙾𝚁𝙴𝚂 𝙳𝙴 𝚂𝙰𝙻𝚄𝙳
𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐧𝐠 𝐚𝐧𝐝 𝐌𝐚𝐧𝐚𝐠𝐢𝐧𝐠 𝐄𝐚𝐫𝐥𝐲-𝐒𝐭𝐚𝐠𝐞 𝐓𝐲𝐩𝐞 𝟏 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐢𝐧 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐏𝐫𝐚𝐜𝐭𝐢𝐜𝐞
Learn how to provide better overall healthcare for individuals at risk of developing or having developed type 1 diabetes.

🚥 𝗦𝘁𝗮𝗿𝘁 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆: https://www.medscape.org/viewarticle/1002609?uac=125644CK&src=mkmcmr_driv_cust_mscpedu_260805-EURO-PCP-1002609-cta
---------------------------------
✔ 𝗘 -𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴: https://www.inaaqc.org/e-learning

28/08/2026

𝐀 𝐫𝐚í𝐳 𝐝𝐞𝐥 𝐞𝐧𝐬𝐚𝐲𝐨 𝐜𝐥í𝐧𝐢𝐜𝐨 𝟒𝐒
En resumen, tras convertirse en genéricas, las estatinas son una terapia económica y bien tolerada con potencial para reducir sustancialmente la carga de la enfermedad vascular aterosclerótica en todo el mundo. Para alcanzar estos objetivos, tanto la accesibilidad como la adherencia son cuestiones fundamentales

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Strandberg, Timo E. In the wake of the Scandinavian Simvastatin Survival Study trial Current Opinion in Lipidology 36(6):p 292-299, December 2025. | DOI: 10.1097/MOL.0000000000001008
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

27/08/2026

𝐅𝐨𝐥𝐥𝐨𝐰𝐢𝐧𝐠 𝐭𝐡𝐞 𝟒𝐒 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥
In summary, after becoming generic, statins are an inexpensive and well-tolerated therapy with the potential to substantially reduce the burden of atherosclerotic vascular disease worldwide. To achieve these goals, both accessibility and adherence are fundamental issues.

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Strandberg, Timo E. In the wake of the Scandinavian Simvastatin Survival Study trial Current Opinion in Lipidology 36(6):p 292-299, December 2025. | DOI: 10.1097/MOL.0000000000001008
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

27/08/2026

E-learning | 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ
---------------------------------
𝙵𝙾𝚁 𝙷𝙴𝙰𝙻𝚃𝙷𝙲𝙰𝚁𝙴 𝙿𝚁𝙾𝚅𝙸𝙳𝙴𝚁𝚂 / 𝙿𝙰𝚁𝙰 𝙿𝚁𝙾𝚅𝙴𝙴𝙳𝙾𝚁𝙴𝚂 𝙳𝙴 𝚂𝙰𝙻𝚄𝙳
𝐀𝐬𝐬𝐞𝐬𝐬𝐢𝐧𝐠 𝐂𝐨𝐠𝐧𝐢𝐭𝐢𝐯𝐞 𝐇𝐞𝐚𝐥𝐭𝐡: 𝐀 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐒𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞
Can you apply the latest guidance to optimize cognitive health? Test your skills.

🚥 𝗦𝘁𝗮𝗿𝘁 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆: https://www.medscape.org/viewarticle/assessing-cognitive-health-medical-simulation-challenge-2026a1000lw3?page=1&src=mkmcmr_driv_psims_mscpedu_260805-OUS-PCP-assessing-cognitive-health-medical-simulation-challenge-2026a1000lw3-cta&uac=125644CK
---------------------------------
✔ 𝗘 -𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴: https://www.inaaqc.org/e-learning

27/08/2026

"𝗝𝐨𝐮𝐫𝐧𝐚𝐥 𝗥𝐞𝐯𝐢𝐞𝐰 (𝐉𝐑)
----------------------------------------------
Performed on: Thursday, July 23, 2026
𝟐𝟎𝟐𝟔 𝐍𝐄𝐉𝐌𝐜 - 𝐎𝐱𝐲𝐠𝐞𝐧 𝐀𝐟𝐭𝐞𝐫 𝐂𝐚𝐫𝐝𝐢𝐚𝐜 𝐀𝐫𝐫𝐞𝐬𝐭, 𝐂𝐨𝐧𝐬𝐞𝐫𝐯𝐚𝐭𝐢𝐯𝐞 𝐯𝐬 𝐋𝐢𝐛𝐞𝐫𝐚𝐥 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲 (𝐍𝐄𝐉𝐌).𝐩𝐝𝐟

1. 𝙄𝙌𝘾 𝙨𝙘𝙤𝙥𝙚 ▶︎ Y, J, C ➖ T ➕ N ➕ t ➖ P I C O:
2. 2026, NEJM, AUS/NZ 🇦🇺 ➖ RCT ➕ 1800 ➕ ❓ (ROSC 25min) ➖ P I C O:
🅿: ROSC MV_OHCA ⌄ IHCA
🅸: conservative O2 (SpO2 90-95%)
🅲: liberal O2 (SpO2 no upper limit + FiO2 0.3)
🅾:
- pOC = SS 180 (functional)
- sOC = MM ➕ …
3. EVIDENCE:
a. O2 can be harmful → IOTA:
i. 2018, LANCET, 🇨🇦
ii. MA ➕ 25 RCT (16k pxs) ➕ ❓
iii. 🅿 acutelly ill adults
iv. 🅸 liberal O2
v. 🅲 conservative O2
vi. 🅾 MM30 + MB
vii. ® rr_MM30 ↑ 🅸 (RR, 1.14)
viii. ∑ logical to test a conservative strategy
b. Conservative strategy was studied:
i. RCT 1 - PILOT
1. 2022, NEJM, Vanderbilt 🇺🇸
2. RCT ➕ 2500 ➕ 3y
3. 🅿 shock (20%) + CA (13%) pxs (ICU + ED)
4. 🅸 🅲 SpO2 high (96-100%), intermediate (92-96%), low (88-92%). Every 2m target adjustment by department.
5. 🅾 MM28 ➕ mv_FD
6.➩ SpO2 (median) 94%, 95%, 97%
7. ➩ FiO2 (median) 0.31, 0.37, 0.,45
8. ® 𝗡𝗢 𝗗𝗜𝗙𝗙

SOURCE ▶︎ The LOGICAL Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen for unresponsive patients after cardiac arrest. N Engl J Med 2026 Jun 10; [e-pub]. DOI: 10.1056/NEJMoa2513814.
𝗩𝗲𝗿 𝗺á𝘀 𝗲𝗻: https://www.inaaqc.org/journal_reviews_2026"

26/08/2026

𝐋𝐃𝐋 𝐂𝐡𝐨𝐥𝐞𝐬𝐭𝐞𝐫𝐨𝐥 𝐚𝐧𝐝 𝐂𝐕 𝐑𝐢𝐬𝐤 𝐢𝐧 𝐭𝐡𝐞 𝐀𝐛𝐬𝐞𝐧𝐜𝐞 𝐨𝐟 𝐂𝐚𝐥𝐜𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬
In conclusion, in symptomatic individuals with a CAC = 0, elevated LDL cholesterol is associated with a higher risk of non-calcified plaque and a higher relative risk of future coronary heart disease events, most pronounced at age ≤45 years. This indicates that long-term LDL cholesterol control remains important in younger individuals despite having a CAC = 0.

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Andersen MH, Jensen JM, Kanstrup H, et al, Low-density lipoprotein cholesterol and cardiovascular risk in the absence of calcifications on computed tomography: the Western Denmark Heart Registry, European Heart Journal, Volume 46, Issue 46, 7 December 2025, Pages 5062–5072, https://doi.org/10.1093/eurheartj/ehaf497
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

26/08/2026

𝐂𝐨𝐥𝐞𝐬𝐭𝐞𝐫𝐨𝐥 𝐋𝐃𝐋 𝐲 𝐫𝐢𝐞𝐬𝐠𝐨 𝐂𝐕 𝐞𝐧 𝐚𝐮𝐬𝐞𝐧𝐜𝐢𝐚 𝐝𝐞 𝐜𝐚𝐥𝐜𝐢𝐟𝐢𝐜𝐚𝐜𝐢𝐨𝐧𝐞𝐬
En conclusión, en individuos sintomáticos con CAC = 0, el colesterol LDL elevado se asocia con un mayor riesgo de placa no calcificada y con un mayor riesgo relativo de eventos futuros de cardiopatía coronaria, más pronunciado a una edad ≤45 años. Esto indica que el control del colesterol LDL a largo plazo sigue siendo importante en individuos más jóvenes a pesar de tener un CAC = 0. .

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Andersen MH, Jensen JM, Kanstrup H, et al, Low-density lipoprotein cholesterol and cardiovascular risk in the absence of calcifications on computed tomography: the Western Denmark Heart Registry, European Heart Journal, Volume 46, Issue 46, 7 December 2025, Pages 5062–5072, https://doi.org/10.1093/eurheartj/ehaf497
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

25/08/2026

"𝗝𝐨𝐮𝐫𝐧𝐚𝐥 𝗥𝐞𝐯𝐢𝐞𝐰 (𝐉𝐑)
----------------------------------------------
Performed on: Thursday, July 23, 2026
𝟐𝟎𝟐𝟔 𝐍𝐄𝐉𝐌𝐜 - 𝐀𝐝𝐞𝐧𝐨𝐬𝐢𝐧𝐞 𝐟𝐨𝐫 𝐒𝐮𝐩𝐫𝐚𝐯𝐞𝐧𝐭𝐫𝐢𝐜𝐮𝐥𝐚𝐫 𝐓𝐚𝐜𝐡𝐲𝐜𝐚𝐫𝐝𝐢𝐚, 𝐒𝐡𝐨𝐮𝐥𝐝 𝐖𝐞 𝐒𝐤𝐢𝐩 𝐭𝐡𝐞 𝟔-𝐦𝐠 (𝐀𝐄𝐌).𝐩𝐝𝐟

1. 𝙄𝙌𝘾 𝙨𝙘𝙤𝙥𝙚 ▶︎ Y, J, C ➖ T ➕ N ➕ t ➖ P I C O:
2. 2026, AEM, TR 🇹🇷 ➖ pros_1c_OBS ➕ 142 ➕ ❓ ➖ P I C O:
🅿: SVT pxs in ED
🅸: initial adenosin 12mg
🅲: initial adenosin 6mg
🅾:
- pOC = conversion rate
- sOC = recurrence ➕ Æ
3. EVIDENCE:
a. GL ▶︎ HD stable + regular narrow-complex SVT:
i. initial adenosine 6mg
ii. then 12mg IF no conversion.
b. retro_OBS ▶︎ consistently show ↗️ conversion w_12mg
4. RESULTS.
a. Conversion rate (p

Adresse

Route De Lennik 804
Brussels

Site Web

https://www.inaaqc.org/

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.